Omp-305b83

Other Medications

Not submitted to EMA

Not available 1 Clinical Trials

Description

OMP-305B83 is an investigational drug, meaning it is still being studied in clinical trials and is not yet approved for treating colorectal cancer or any other condition. It is being investigated by OncoMed Pharmaceuticals, Inc. Specifically, it has been studied in Phase 1 trials for people with metastatic colorectal cancer (cancer that has spread to other parts of the body). These trials, like NCT03035253, are designed to determine the best dose and assess the safety and potential effectiveness of OMP-305B83 when given alongside standard chemotherapy regimens like FOLFIRI (containing irinotecan and leucovorin) or FOLFOX (containing oxaliplatin and leucovorin). The goal of these early-stage trials is to see if adding OMP-305B83 to existing treatments can improve outcomes for patients with advanced colorectal cancer. As it is still investigational, its long-term benefits and risks are not yet fully known.

Mechanism of Action

OMP-305B83 is being studied as a potential treatment for colorectal cancer. The specific way it works (its mechanism of action) is being investigated in clinical trials. It is designed to target specific proteins involved in tumor growth and survival. The trials aim to understand how OMP-305B83 interacts with these targets and its overall effect on cancer cells.

Side Effects

Because OMP-305B83 is an investigational drug in early-phase trials (Phase 1) Detailed information about its side effects is still being gathered. The primary focus of Phase 1 trials is to assess safety and determine the maximum tolerated dose. While specific side effects from the trials are not detailed here Patients participating in these trials are closely monitored for any adverse events. Common side effects associated with the chemotherapy regimens used in combination (like FOLFIRI or FOLFOX) include nausea Vomiting Diarrhea Fatigue And changes in blood counts. The side effects specific to OMP-305B83 are still being evaluated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03035253 Phase 1

Archived

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

United States

Quick Info

Category	Other Medications
EMA Status	Not submitted to EMA
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.